==== Front Degener Neurol Neuromuscul DisDegener Neurol Neuromuscul DisDegenerative Neurological and Neuromuscular DiseaseDegenerative Neurological and Neuromuscular Disease1179-9900Dove Medical Press 10.2147/DNND.S34251dnnd-3-053ReviewAn update on the management of young-onset Parkinson’s disease Klepac Nataša 1Habek Mario 1Adamec Ivan 1Barušić Anabella Karla 1Bach Ivo 1Margetić Eduard 2Lušić Ivo 3 1 Department of Neurology, Clinical University Hospital Zagreb, Medical School, University of Zagreb, Zagreb, Croatia, natasa.klepac@zg.t-com.hr 2 Department of Cardiology, Clinical University Hospital Zagreb, Medical School, University of Zagreb, Zagreb, Croatia 3 Department of Neurology, Clinical University Hospital, Medical School, University of Split, Split, CroatiaCorrespondence: Nataša Klepac, Department of Neurology, Clinical University Hospital Zagreb, Medical School, University of Zagreb, Kišpatićeva 12, Zagreb 10000, Croatia, Tel +385 9 854 1880, Fax +385 1 238 8784, Email natasa.klepac@zg.t-com.hr2013 04 10 2013 2 53 62 © 2013 Klepac et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License2013The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.In the text that follows, we review the main clinical features, genetic characteristics, and treatment options for Parkinson’s disease (PD), considering the age at onset. The clinical variability between patients with PD points at the existence of subtypes of the disease. Identification of subtypes is important, since a focus on homogenous group may lead to tailored treatment strategies. One of the factors that determine variability of clinical features of PD is age of onset. Young-onset Parkinson’s disease (YOPD) is defined as parkinsonism starting between the ages of 21 and 40. YOPD has a slower disease progression and a greater incidence and earlier appearance of levodopa-induced motor complications; namely, motor fluctuations and dyskinesias. Moreover, YOPD patients face a lifetime of a progressive disease with gradual worsening of quality of life and their expectations are different from those of their older counterparts. Knowing this, treatment plans and management of symptoms must be paid careful attention to in order to maintain an acceptable quality of life in YOPD patients. Keywords therapyclinical featuresdopamine agonistlevodopadyskinesia ==== Body Introduction Young-onset Parkinson’s disease (YOPD) is a subtype of Parkinson’s disease (PD), occurring at a younger age, with specific symptoms, genetic correlation, and treatment strategies. YOPD is defined as the diagnosis of PD between the ages of 21 and 40.1 A positive PD diagnosis under the age of 21 is referred to as “juvenile Parkinson’s” (JP). Between 3% and 6% of all PD cases are reported to be YOPD.1–3 Although most clinical features of JP and YOPD are the same, increased occurrence of dystonia and PD are found in families of patients with JP.4 The overall age and gender adjusted incidence of PD is 13.4 per 100,000, whereas the incidences for people between the ages of 30 and 39, 40 and 49, and 50 and 59 are 0.5, 2.5, and 9.8 per 100,000, respectively.5 Approximately 20% of YOPD patients have at least one first- or second-degree relative with PD either in the same or antecedent generation.6 The aim of this review is to give an overview of specific clinical manifestations, genetic background, and potential environmental factors of YOPD with strong focus on current treatment options and strategies available for YOPD. Clinical manifestations Although the diagnosis of YOPD is based on clinical symptoms and family history of Parkinson’s disease or any other movement disorders, there must be exclusion of secondary causes of parkinsonian symptoms. Some of these secondary causes include Wilson’s disease, dopa-responsive dystonia, drug-induced parkinsonism, spinocerebellar ataxia, iron accumulation disorders, and structural abnormalities. To exclude these possible secondary causes, such as drug-induced parkinsonism, a detailed history of all neuroleptic and antiemetic drug use should be recorded. Measurement of serum and urinary copper, and screening for Kayser–Fleischer rings should be performed to exclude Wilson’s disease. Motor symptoms The classical clinical appearance of PD consists of a resting tremor (3–6 Hz, usually unilateral on presentation), cogwheel rigidity, bradykinesia, and sometimes compromised postural reflexes and gait instability.7,8 Another sign, which is 100% sensitive but not completely specific for PD, may be a positive response to levodopa.7 The symptoms that appear in YOPD are similar to the classical symptoms of late-onset PD (LOPD), but some clinical features seem to be more prominent in YOPD. In one study comparing clinical symptoms of YOPD versus LOPD it was concluded that YOPD patients more commonly present with increased muscle stiffness (43%), while LOPD patients more often present with increased difficulty walking later on in the illness (33%).9 Postural instability is more commonly seen in LOPD than in YOPD.1 It was shown that “wearing-off,” “on–off ” dystonia, and levodopa dyskinesia10 as well as dyskinesia in general11 were much more prominent in YOPD patients (59% versus 37%).12 Although, as previously mentioned, this very well could be a side effect of therapy.1,11,13,14 More specifically, it has been demonstrated that the most common type of dyskinesia is peak-dose dyskinesia, which includes stereotypic, choreic, or ballistic movements involving the head, trunk, limbs, and occasionally respiratory muscles.15–17 Another study confirming these findings showed that about one-third of YOPD patients had off-period dystonia, while LOPD patients were not observed to have dystonia during the study.9 The differences observed in the prevalence of tremor and bradykinesia between YOPD and LOPD were not statistically significant.10 YOPD patients were also shown to have increased motor fluctuations (69%) in comparison to LOPD patients (46%).12 In JP dystonia (60% in JP versus 14% for YOPD) and akinetic rigidity (69% in JP versus 20% for YOPD) are much more common.18 Non-motor symptoms It has been demonstrated that after median disease duration of 18 years, the prevalence of cognitive impairments is only 19%, of which 13% is under the age of 60.19 YOPD patients have a decreased incidence of cognitive degeneration when compared with LOPD.1,18–20 It has been postulated that there may be a difference in the types of Parkinson’s between YOPD and LOPD with motor deterioration predominating the symptoms of YOPD and mental deterioration predominating the symptoms of LOPD.21 YOPD patients have been shown to have many psychological symptoms such as psychosis, confusion, and even hallucinations; these symptoms were present in only 13% of patients who had disease duration less than 10 years, and positively correlated with the duration of disease.18 Depression was also correlated with YOPD, this was postulated to possibly be a consequence of a longer duration of disease and decreased quality of life due to a high prevalence of motor symptoms.22 It was found that the mortality rate associated with YOPD is twice that of the normal population, but when compared with other PD patients it does not statistically vary.2,23,24 Paresthesias were also found to be in 20.5% of YOPD patients compared with 2% of the LOPD patients.11 Other non-motor symptoms, which were found to be more common in YOPD patients in comparison with LOPD patients, were restless legs and sweating.12 The presence of symptoms in YOPD and LOPD is shown in Table 1. Diagnosis The diagnosis of YOPD is still widely based on the judgment of clinical symptoms. The recently US Food and Drug Administration (FDA)-approved DaTSCAN is being questioned for its accuracy and overall contribution to the diagnosis of PD. It has been shown that the overall accuracy of clinical diagnosis is 84% in early PD and 98% at later stages of PD. The diagnosis of PD clinically is mathematically just as accurate as the diagnostic accuracy of DaTSCAN imaging.25 It must be kept in mind that the purpose of a DaTSCAN is to aid in the diagnosis of PD and not to be a replacement of the clinical diagnosis. It has also been shown that transcranial ultrasound can show hyperechogenicity in the substantia nigra of a PD patient.26–28 It has been postulated that this is due to the increased concentration of iron in some patients with PD.26–29 Furthermore, lower serum ceruloplasmin levels have been correlated with a younger onset of PD.26 Genetic background and potential environmental factors in YOPD The genetic contribution to the etiology of YOPD is probably greater than in PD with later onset.30 Out of several genes, assumed to be associated with YOPD, five stand out and are mentioned more frequently in current literature than others (Table 2).31 Mutations in the PARK2 gene are the most common cause of autosomal recessive YOPD31–34 with an onset before age 40.35 PARK2 is an E3-type ubiquitin protein ligase involved in the proteosomal degradation of target proteins, including α-synuclein.36 The accumulation of this protein results in neuronal death in substantia nigra and locus ceruleus.36 The second most common cause of autosomal recessive YOPD is PINK1 gene mutation. The discovery of PINK1 involvement in PD was the first evidence that a kinase signaling pathway could be important in the pathogenesis of dopaminergic nigral cell death.37 Moreover, it provided a link between mitochondrial dysfunction and neurodegeneration seen in PD.38,39 Another gene thought to be associated with YOPD is PARK7, involved in protection from oxidative stress and chaperoning proteins such as α-synuclein.36 PD associated with LRRK2 mutations presents an onset distribution very similar to that seen in idiopathic PD, as well as clear age-dependent penetrance.40–42 In 2009, Tong et al demonstrated that LRRK2 mutation affects activity-dependent dopamine (DA) neurotransmission and catecholamine release.43 Lastly, mutations in SNCA, although rare, cause PD to occur at a younger age than that seen for idiopathic PD.44 Given the correlation described recently between LRRK2 and SNCA45,46 and the impact of α-synuclein overexpression on synaptic vesicle recycling,47 the regulation of neurotransmitter release might arise as one of the main biological pathways compromised during neuropathology onset.48 Additionally, a study conducted by Nichols et al suggests that patients carrying a glucocerebrosidase (GBA) variant exhibited PD symptoms 6.04 years earlier than those without a GBA variant.49 It is also important to note that the abovementioned LRRK2, SCNA, and GBA gene mutations increase the risk of sporadic PD, whereas many others are linked to familial forms of PD. Apart from genes, environmental factors may also play a role in YOPD etiology. A study from Sao Paulo by Aguiar at al observed higher exposure to well-water drinking in the YOPD patient group. Most of the patients were exposed during first or second decades of life, for an average period of 14.3 years.34 Other potential environmental risk factors included pesticides, herbicides, and organic solvents. An inverse association between smoking and PD risk was not observed, suggesting a putative protective effect smoking might have on PD development. However, the authors argued that in the case of YOPD, the protective effects of smoking were not enough to overcome all other factors leading to neurodegeneration. Current treatment options and strategies available for YOPD Pharmacological treatment Which drugs to use when initiating pharmacotherapy in YOPD is a complex treatment decision that depends on factors such as disease severity, functional disability, and psychosocial handicap, as well as individual aspects of comorbidity and age. To date, the most effective treatment for PD has been shown to be levodopa. It is effective in treating symptoms such as bradykinesia and rigidity. The effects of levodopa on postural stability, speech, and gait disturbance is less pronounced. Initially, YOPD patients have a good response to levodopa therapy, but as treatment progresses, motor symptoms resistant to levodopa develop.6,13,21 It seems that YOPD patients have a slower progression of disease but higher treatment complications with levodopa.1,11,13,14 In YOPD, treatment with levodopa is associated with early and prominent occurrence of motor complication, namely dyskinesia. In one study, it was observed that within the first week of treatment with levodopa, 25% of patients developed a complication; after 5 years of levodopa treatment, 91% of patients developed dyskinesias, and 92% developed motor fluctuations; and after 12 years, all patients had those side effects.21 A similar trend was demonstrated by a study done in 1987, where 100% of patients developed dyskinesias by the sixth year after therapy.6 Therefore, the treatment with levodopa should be postponed in this group of patients, although every PD patient progresses to the point where levodopa is necessary.50 Alternative treatment options to start therapy in YOPD are dopamine agonists, inhibitors of monoamine oxidase B (selegiline hydrochloride, or rasagiline mesilate), amantadine hydrochloride, or where tremor is a particular problem, anticholinergics – although use of the latter might be restricted by cognitive side-effects.51,52 All of these drugs can be used alone or in combination with levodopa to successfully treat PD. The decisions as to when to start drug treatment and which drugs to use in patients with YOPD depend on several factors, including disease severity, functional disability, comorbidity, personal expectations, employment status, and psychosocial handicap.50 Evidence suggests that the use of dopamine agonists rather than levodopa is associated with a decreased risk of developing motor complications.53–57 Long-term follow-up trials have confirmed that there are fewer dyskinesias and motor fluctuations in patients treated with dopamine agonists, but a decrease in moderate to severe dyskinesias was not noted to be very significant.58–60 This delay of dyskinesias and motor complications may be most appreciated in patients with YOPD.61 There is also some evidence that dopamine agonists may have a neuroprotective effect.62 This has been supported by functional imaging studies which demonstrate a decreased rate of decline of presynaptic dopaminergic functions.63,64 However, this conclusion comes from correlating the changes in imaging techniques rather than the clinical picture. Nonetheless, this information has led us to believe that starting therapy with dopamine agonists rather than levodopa could be beneficial. However, one must keep in mind that dopamine agonists also have many side effects. In PD patients treated with dopamine agonists, impulse control disorders including gambling, shopping, binge eating, and hypersexuality are observed. Other observed side effects of dopamine agonists are increased daytime sleepiness, leg edemas, and early hallucinations.65–67 However, the method of treatment which has been most supported for YOPD is initiation of treatment with dopamine agonists, increasing the dose until a balanced level of effectiveness and the level of maximum tolerance is reached. Levodopa is then added as adjuvant therapy as needed.68,69 This method of therapy seems most suitable in YOPD for avoiding early motor symptoms due to levodopa treatment. Monoamine oxidase (MAO)-B inhibitors are effective in monotherapy and as an adjunct to levodopa therapy, with beneficial effects on quality of life parameters in early and late stages of PD. Studies have shown that MAO-B inhibitors reduce the incidence of motor fluctuations, decrease the need for levodopa, and reducing overall disability, with negligible side effects. The MAO-B inhibitors, used as monotherapy, delay the need for the introduction of levodopa by about 9 months. These agents appear to be less efficacious than dopamine agonists but are better tolerated.70 Amantadine could be used as a monotherapy or in combination with levodopa. There is some evidence that amantadin is useful in controlling dyskinesias, but evidence of its effectiveness in treating motor complications has not been convincing.71,72 Amantadine has been shown to reduce dyskinesia by 45% in patients with PD when it was compared with a placebo, but the positive effects were only sustained for 8 months, and when the patient experienced withdrawal from amantadine, there was an up to 20% increase in dyskinesias.73 Therefore, amantadine is usually used as add-on therapy when dyskinesias develop. Anticholinergics are nowadays rarely used due to side effects such as cognitive disturbances. Sometimes one may consider using anticholinergics for treatment of severe tremor in YOPD. The therapeutic approach differs in late and early phase of PD. In the late stage of PD in YOPD, motor complications such as wearing-off, unpredictable offs, and dyskinesias predominate. Therefore addition and manipulation of doses of levodopa, dopamine agonists, MAO-B inhibitors, and inhibitors of catechol-O-methyltranferase (COMT) can all be helpful in improving these complications. COMT inhibitors in combination with levodopa enhance efficacy of levodopa on motor symptoms of PD due to prolongation of its effect. Despite all the therapeutic possibilities for treating YOPD, one must bear in mind that YOPD patients face a lifetime of a progressive disease and many years of therapy. When manipulations of oral antiparkinsonian drugs are exhausted, patients with YOPD may be good candidates for continuous apomorphine infusions, surgery, or continuous levodopa treatment. For years it was believed that levodopa may have been toxic to dopaminergic neurons.74,75 Performance of levodopa infusions is a rather complex and expensive technique, which was a reason for restricting levodopa therapy for many years. Now opinions are changing, and it is believed that the decreased response to levodopa in late Parkinson’s is due to progression of disease rather than toxic effects.76 Moreover, it is thought that continued delivery of levodopa to the brain help to prevent and improve motor complications. Physiological continuous stimulation of the dopaminergic neurons has been explored through duodenal, intrajejunal, or subcutaneous infusions. It has been shown that continuous stimulations improve motor symptoms.77 Surgery Deep brain stimulation (DBS) DBS is an FDA-approved surgical technique whereby electrical current is applied to various parts of the brain via implanted electrodes.78 In contrast to ablative procedures, it proves to be a safer method in the treatment of movement disorders, producing adverse effects that are generally reversible once the stimulation is terminated.79 The underlying mechanisms of DBS are not completely understood, although growing evidence supports the efficacy of DBS for the treatment of movement disorders including PD.79 Over the years, many targets have been used for the treatment of PD, including ventral intermediate nucleus (VIM), subthalmic nucleus (STN), and globus pallidus interna (GPi).79 Benabid et al found that in a series of 80 PD patients treated with either unilateral or bilateral VIM DBS, 88% had complete or near-complete tremor relief on the Fahn–Tolosa–Marin Tremor Rating Scale at 6 months to 8 years postoperatively.80 The effects of VIM DBS on other symptoms of PD such as rigidity, bradykinesia, or drug-induced dyskinesia were either short lasting or nonexistent.80 STN DBS does not improve on-medication state UPDRS motor subscores but does lead to 52% improvement in the off-medication state UPDRS scores over a period of 15 months postoperatively.81 A 50%–60% reduction in postoperative levodopa dose leads indirectly to improvement in levodopa-induced dyskinesia.81,82 On-medication dyskinesias are reduced by 94% after 12 months of STN DBS.82 Quality of life is significantly improved after STN DBS compared with medical therapy.78,83 However, recent data suggest that, although STN DBS improves motor components in both young and old patients, it is less effective in patients older than 65.84 Nevertheless, a recent study by Odekerken et al suggests that STN could be the preferred target for DBS in patients with advanced PD.85 DBS-associated problems in cognitive, mood, and behavioral features seem to occur more often in the STN stimulation.85–89 In PD patients, GPi DBS improves tremor, rigidity, and bradykinesia in off-medication state as well as drug-induced bradykinesia, resulting in overall improvement in UPDRS motor scores.90–92 The most pronounced and long-lasting effect is the reduction in on-medication dyskinesia.93 GPi DBS does not lead to reduction in the patient’s levodopa requirement and might even increase after chronic GPi DBS therapy.94 YOPD patients are usually char-acterized by a slower disease progression, lower incidence of non-levodopa responsive symptoms, and more severe motor complications,18,95–97 thus representing ideal candidates for the DBS surgical option.98 A study by Merola et al showed that STN DBS-treated YOPD patients were associated with a medium- to long-term lower incidence of stimulation and medication resistant symptoms.98 Ablation Currently, the options for ablation therapy include pallidotomy or thalamotomy, where the target structure may either be the globus pallidus or the thalamus. Palidotomy has been shown to reduce drug-induced dyskinesias and dystonias in PD patients who have previously had a successful response to pharmacological therapy.99 A unilateral pallidotomy usually improves symptoms on the contralateral side.100 There is a dispute whether a bilateral pallidotomy is a completely safe procedure.101 As with the pallidotomy a unilateral thalamotomy will be effective against symptoms on the contralateral side. It may improve tremor, rigidity, and dyskinesias but may worsen other parkinsonian symptoms such as bradykinesia, gait problems, postural instability, or speech disorders.74,102 Currently there is a new noninvasive method which is emerging and has been approved by the FDA to enroll 30 patients in its study for ablation by transcranial magnetic resonance (MR) imaging-guided focused ultrasound.102 It uses focused ultrasound waves, which converge at a specific point determined and guided by MR to ablate the malfunctioning structure in the brain (nucleus ventralis intermidius of the thalamus). The procedure includes real-time continuous MR imaging and MR thermometry monitoring, creating a very precise, safe, and effective way to treat patients.100,102–104 Novel therapies Emerging therapeutic options for treating idiopathic PD, such as neurotrophic factors, cell-based therapy, neurotransmitter targets, and potentially neuroprotective drugs, are generating much interest but also controversy.105–108 Most recent treatment options for PD involve immunotherapy through vaccination and gene therapy. However, most of these treatment options focus very little on the YOPD subgroup of patients. Further research is needed to test their efficacy on YOPD patients specifically. These therapies are currently in experimental stages of development and have not been FDA approved. Cell-based therapy Cell-based therapy for PD has shown significant progress in recent years.104 A major advancement came with the use of fetal ventral mesencephalic (VM) tissue as a cell source for transplantation. Fetal dopamine (DA) neurons transplanted into the striatum of PD patients have survived, integrated, and provided motor benefits.109–111 The first neural transplantation used dissociated fetal VM tissue, which was transplanted into the striatum of young PD patients. Marked motor improvement and increased fluorodopa uptake in the striatum on positron emission tomography (PET) was observed.109 Indirect evidence of graft survival, obtained from PET studies, indicated that the transplanted fetal VM tissue can survive up to a decade and provide sustained motor benefits in PD.112 Additionally, it was shown that DA neuronal suspension grafts can survive, integrate, and display mature VM phenotypes providing functional benefits in the degenerating brain for years without side effects such as dyskinesia.113 In a trial with solid pieces of fetal VM tissue, clinical improvement was, to some degree, observed in YOPD but not in non-YOPD patients.111 Immunotherapy PD, as the second most common neurodegenerative entity, is of particular interest with regard to applying immunotherapy in clinical practice.88 The major component of Lewy bodies, and neuropathological hallmark of PD, is α-synuclein.88 The first experimental indication that α-synuclein might be the causative agent in PD came from the analysis of rare autosomal dominant forms of PD in several families carrying three different point mutations in the SNCA gene leading to the formation of misfolded protein.88 Masliah et al investigated mice overexpressing human SNCA and either administrated a full-length α-synuclein-based vaccine employing CFA/IFA (Freund’s complete/incomplete adjuvant) as adjuvant89 or systemically administrated an α-synuclein-specific monoclonal antibody.114 Both therapies were associated with reduced neurodegeneration and improved function. Recently, AFFITOPE® PD01 vaccine has been developed to induce antibodies recognizing α-synuclein.88 Preclinical studies involving the subcutaneous administration of the vaccine demonstrated reactivity towards α-synuclein with an additional functional benefit.88 Compared with controls, PD01-treated animals showed superior cognitive functions as assessed by the Morris water maze test.88 Gene therapy In-vivo gene therapy is a new approach.115 Gene transfer of glutamic acid decarboxylase (GAD), rate-limiting enzyme in gamma-aminobutyric acid (GABA) production, and other methods that modulate the production of GABA in the subthalmic nucleus, improve basal ganglia function in parkinsonism in animal models.115 LeWitt et al assessed the effect of bilateral delivery of adeno-associated viral vector (AAV2)-GAD in the subthalmic nucleus compared with sham surgery in patients with advanced PD. The AVV2-GAD group showed significant improvement from baseline in unified PD rating scale (UPDRS) scores compared with sham group over the course of 6 months.115 A similar study involving neurturin, a naturally occurring analogue of glial cell-line-derived neurotrophic factor, was conducted by Marks et al116 by bilateral delivery of AAV2-neurturin into the putamen. However, it showed no motor score improvement using the UPDRS in treated patients after 12 months.116 The selection of the best candidate for surgery among PD patients is a debated topic. YOPD patients could be the best candidates for this kind of treatment, because they have a slower disease progression and more competent compensatory mechanisms, and this could be beneficial for effects of transplantations.117 Adjuvant therapies Physical and occupational therapy in YOPD patients should be used with pharmacological treatment and may assist in the rehabilitation process. Initiating an exercise program from the earliest stages of PD might benefit secondary motor problems involving arm swing, gait, and posture.118,119 Exercise has been shown to improve physical function, health-related quality of life, leg strength, balance, and gait speed in PD, and is possibly mediated through increased calcium/CaM-dependent dopamine synthesis in the remaining dopaminergic nigrostriatal cells.120,121 Service (trained) dogs are reported to help people with PD by interruption of rest tremor on stroking the dog and diminishing propulsive gait,118 perhaps by providing visual cues.122 YOPD patients with speech difficulties might benefit from intensive voice therapy to maintain employment and social activity.115 Conclusion Many clinicians view age at onset as an important determinant of clinical phenotype in PD. YOPD is very similar to LOPD in many ways but requires special attention because it is different enough to require a different treatment approach. The available evidence suggests that PD patients with younger age at onset have slower disease progression, an increased rate of dystonia at onset, a lower rate of dementia, and an increased rate of dyskinesias in response to levodopa treatment. Which drugs to use when initiating pharmacotherapy in YOPD is a complex treatment decision that depends on factors such as disease severity, functional disability, and psychosocial handicap, as well as individual aspects of comorbidity and age. Without clear proof of a drug’s capacity to markedly alter or even stop the progression of the disease, there is no strategy that can be viewed as universal treatment. Dopamine replacement strategies offer greatest symptomatic relief and are needed whenever there is significant functional disability. Physicians are slowly gravitating towards the notion that levodopa treatment does not have toxic effects on dopaminergic neurons; however, preventing dyskinesias and motor symptoms which begin shortly after levodopa treatment initiation in YOPD patients remains to be demonstrated. The therapeutic strategy for YOPD patients should include a relatively low threshold for initiation of treatment. The treatment should be initiated with a dopamine receptor agonist, with the dosage individually adjusted. In the cases where the treatment response is suboptimal, or if problematic adverse effects develop, levodopa should be added to the therapy. YOPD patients are also ideal candidates for DBS therapy with medium- to long-term lower incidence of stimulation and medication resistant symptoms. Regular physical exercise and physical therapy must be encouraged. Emerging therapeutic options for the treatment of YOPD, such as cell-based therapy are generating much interest from the scientific community, although their effectiveness remains to be established. Future therapeutic strategies should focus not only on ameliorating the symptoms of PD, but also on neuroprotective or neurorescue therapies that can favorably modify the natural course of the disease and slow the progression of manifestations of PD. YOPD patients are not only bearing the burden of motor complications but psychological problems, often overlooked, and a general decrease in the quality of life. Many studies have shown that proper treatment can significantly increase the quality of life in YOPD patients. For this reason, a custom tailored treatment plan is of interest, based on stage of the disease, degree of interference of the symptoms with social and occupational functioning, and response to treatment. The medical management of YOPD is complicated, and a multidisciplinary approach to care is vital to meet the psychological, emotional, and social needs of PD patients and their families. Key points Diagnosis of PD before the age of 40 is considered YOPD. When suspecting YOPD, secondary causes of parkinsonian symptoms should be excluded (Wilson’s disease, dopa-responsive dystonia, drug-induced parkinsonism, and structural abnormalities). After 6 years of levodopa therapy, almost all YOPD patients develop dyskinesias. Starting therapy with dopamine agonists delays the onset of levodopa-related motor symptoms until therapy with levodopa is initiated. DBS and ablation are available surgical options in the treatment of YOPD. Cell-based therapy, immunotherapy, and gene therapy are emerging therapeutic options in YOPD treatment. Physical and occupational therapy in YOPD patients should be used as an adjuvant therapy and may assist in the rehabilitation process. Disclosure The authors report no conflicts of interest in this work. Table 1 Occurrence of symptoms in young- and late-onset Parkinson’s disease Young-onset Parkinson’s disease Late-onset Parkinson’s disease • Motor fluctuations • Postural instability • “Off-time” dystonia • Difficulty walking • Muscle stiffness • Cognitive degeneration • Dyskinesia • Psychosis, confusion, hallucinations • Depression • Paresthesias • Restless legs • Sweating Table 2 Genes found to be significant in young-onset Parkinson’s disease etiology and their mode of inheritance Mode of inheritance Autosomal recessive Gene product Function PARK2 (OMIM*602544) Parkin Plays a role in the cell machinery that degrades unneeded proteins PINK1 (OMIM*608309) PTEN induced putative kinase 1 Helps protect mitochondria from malfunctioning during period of cellular stress PARK 7 (OMIM*602533) DJ-1 protein Helps protect cells from oxidative stress Autosomal dominant LRRK2 (OMIM*609007) Dardarin Plays a role in activities that require interactions with other proteins, such as transmitting signals SNCA (OMIM*163890) α-synuclein Plays a role in maintaining a supply of synaptic vesicles in presynaptic terminals ==== Refs References 1 Golbe LI Young-onset Parkinson’s disease: a clinical review Neurology 1991 41 2 168 173 1992358 2 Martilla RJ Rine UK Epidemiology of Parkinson’s disease in Finland Acta Neurol Scand 1976 53 2 81 102 1266565 3 Schrag A Ben Shlomo Y Quinn NP Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London BMJ 2000 321 7252 21 22 10875828 4 Muthane UB Swamy HS Satishchandra P Subhash MN Rao S Subbakrishna D Early onset Parkinson’s disease: are juvenile- and young-onset different? Mov Disord 1994 9 5 539 544 7527483 5 Stephen K Van Den Eeden C Tanner M Incidence of Parkinson’s Disease: variation by age, gender, and race/ethnicity Am J Epidemiol 2003 157 11 1015 1022 12777365 6 Quinn N Critchley P Marsden CD Young onset Parkinson’s disease Mov Disord 1987 2 2 73 91 3504266 7 Gelb DJ Oliver E Gilman S Diagnostic Criteria for Parkinson Disease Arch Neurol 1999 56 1 33 39 9923759 8 Calne DB Snow BJ Lee C Criteria for diagnosing Parkinson’s Disease Ann Neurol 1992 32 Suppl 125 127 9 Gibb WRG Lees AJ A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease Neurology 1988 38 9 1402 1406 3412587 10 Jankovic J Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations Mov Disord 2005 20 11 11 16 15455447 11 Friedman A Old-onset Parkinson’s disease compared with young-onset disease: clinical differences and similarities Acta Neurol Scand 1994 89 4 258 261 8042442 12 Spica V Pekmezović T Svetel M Kostić VS Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s disease J Neurol 2013 260 1 131 137 22820720 13 Pantelatos A Fornadi F Clinical features and medical treatment of Parkinson’s disease in patient groups selected in accordance with age at onset Adv Neurol 1993 60 690 697 8420212 14 Ku S Glass GA Age of Parkinson’s disease onset as a predictor for the development of dyskinesia Mov Disord 2010 25 9 1177 1182 20310028 15 Rascol O Levodopa-induced peak-dose dyskinesias in patients with Parkinson’s disease: a clinical pharmacologic approach Mov Disord 1999 14 1 19 32 10493400 16 Jankovic J Nour F Respiratory dyskinesia in Parkinson’s disease Neurology 1986 36 2 303 304 17 Rice JE Antic R Thompson PD Disordered respiration as a levodopa-induced dyskinesia in Parkinson’s disease Mov Disord 2002 17 3 524 527 12112201 18 Schrag A Ben-Shlomo Y Brown R Marsden CD Quinn N Young-onset Parkinson’s disease revisited – clinical features, natural history, and mortality Mov Disord 1998 13 6 885 894 9827611 19 Goetz CG Tanner CM Stebbins GT Buchman AS Risk factors for progression in Parkinson’s disease Neurology 1988 38 12 1841 1844 3194061 20 Hietanen M Teravainen H The effect of aging and onset on neuropsychological performance in Parkinson’s disease J Neurol Neurosurg Psychiatry 1988 5 1 244 249 21 Lieberman A Dziatolowski M Kupersmith M Dementia in Parkinson’s disease Ann Neurol 1979 6 355 359 554525 22 Knipe MD Wickremaratchi MM Wyatt-Haines E Morris HR Ben-Shlomo Y Quality of life in young- compared with late-onset Parkinson’s disease Mov Disord 2011 26 11 2011 2018 21574185 23 Ben-Shlomo Y Marmot MG Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995 58 3 293 299 7897409 24 Bennett DA Beckett LA Murray AM Prevalence of parkinsonian signs and associated mortality in a community population of older people N Engl J Med 1996 334 2 71 76 8531961 25 De la Fuente-Fernández R Role of DaTSCAN and clinical diagnosis in Parkinson disease Neurology 2012 78 10 696 701 22323748 26 Bharucha KJ Friedman JK Vincent AS Ross ED Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease J Neurol 2008 255 12 1957 1962 19159062 27 Hochstrasser H Bauer P Walter U Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease Neurology 2004 63 1912 1917 15557511 28 Berg D Hochstrasser H Schweitzer KJ Riess O Disturbance of iron metabolism in Parkinson’s disease – ultrasonography as a biomarker Neurotox Res 2006 9 1 1 13 16464747 29 Gotz ME Double K Gerlach M Youdim MB Riederer P The relevance of iron in the pathogenesis of Parkinson’s disease Ann N Y Acad Sci 2004 1012 193 208 15105267 30 Rissling I Strauch K Höft C Oertel WH Möller JC Haplotype analysis of the engrailed-2 gene in young-onset Parkinson’s disease Neurodegenerative Dis 2009 6 3 102 105 31 Macedo MG Verbaan D Fang Y Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson’s disease Mov Disord 2009 24 2 196 203 18973254 32 Choi JM Woo MS Ma HI Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease Neurogenetics 2008 9 4 263 269 18704525 33 Guo JF Zhang XW Nie LL Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism J Neurol 2010 257 7 1170 1175 20146068 34 Aguiar Pde C Lessa PS Godeiro C Jr Genetic and environmental findings in early-onset Parkinson’s disease Brazilian patients Mov Disord 2008 23 9 1228 1233 18464276 35 Latourelle JC Pankratz N Dumitriu A Genomewide association study for onset age in Parkinson disease BMC Med Genet 2009 10 98 19772629 36 Pankratz N Foroud T Genetics of Parkinson disease Genet Med 2007 9 12 801 811 18091429 37 Keyser RJ Lesage S Brice A Carr J Bardien S Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson’s disease Biochem Biophys Res Commun 2010 398 1 125 129 20558144 38 Valente EM Abou-Sleiman PM Caputo V Hereditary early-onset Parkinson’s disease caused by mutations in PINK1 Science 2004 304 5674 1158 1160 15087508 39 Abou-Sleiman PM Muqit MM McDonald NQ A heterozygous effect for PINK1 mutations in Parkinson’s disease? Ann Neurol 2006 60 4 414 419 16969854 40 Nichols WC Pankratz N Hernandez D Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease Lancet 2005 365 9457 410 412 15680455 41 Latourelle JC Sun M Lew MF The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson’s Disease: the GenePD study BMC Med 2008 6 1 32 18986508 42 Goldwurm S Zini M Mariani L Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease Neurology 2007 68 14 1141 1143 17215492 43 Tong Y Pisani A Martella G R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice Proc Natl Acad Sci U S A 2009 106 34 14622 14627 19667187 44 Polymeropoulos MH Lavedan C Leroy E Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease Science 1997 276 5321 2045 2047 9197268 45 Lin X Parisiadou L Gu XL Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein Neuron 2009 64 6 807 827 20064389 46 Carballo-Carbajal I Weber-Endress S Rovelli G Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway Cell Signal 2010 22 5 821 827 20074637 47 Nemani VM Lu W Berge V Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis Neuron 2010 65 1 66 79 20152114 48 Piccoli G Condliffe SB Bauer M LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool J Neurosci 2011 31 6 2225 2237 21307259 49 Siegel GJ Chauhan NB Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain Brain Res Rev 2000 33 2–3 199 227 11011066 50 Stoessl J Potential therapeutic targets for Parkinson’s disease Expert Opin Ther Targets 2008 12 4 425 436 18348679 51 Ross OA Soto-Ortolaza AI Heckman MG Genetic Epidemiology Of Parkinson’s Disease (GEO-PD) Consortium Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control study Lancet Neurol 2011 10 10 898 908 21885347 52 Schapira AH Future directions in the treatment of Parkinson’s disease Mov Disord 2007 22 17 385 391 53 Rascol O Brooks DJ Korczyn AD Development of dyskinesias in a 5-year trial of ropinirole and L-dopa Mov Disord 2006 21 11 1844 1850 16958094 54 Holloway RG Shoulson I Fahn S Pramipexole vs levodopa as initial treatment for Parkinson disease a 4-year randomized controlled trial Arch Neurol 2004 61 7 1044 1053 15262734 55 Rascol O Brooks DJ Korczyn AD De Deyn PP Clarke CE Lang AE A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 2000 342 20 1484 1491 10816186 56 Oertel WH Wolters E Sampaio C Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET study Mov Disord 2006 21 3 343 353 16211594 57 Rinne UK Bracco F Chouza C Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications – results of a double-blind levodopa controlled trial Drugs 1998 55 Suppl 1 23 23 9483167 58 Lees AJ Katzenschlager R Head J Ben Shlomo Y Ten year follow up of three differentinitial treatments in de-novo PD: a randomized trial Neurology 2001 57 9 1687 1694 11706112 59 Hauser RA Rascol O Korczyn AD Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa Mov Disord 2007 22 16 2409 2417 17894339 60 Parkinson Study Group CALM Cohort Investigators Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease Arch Neurol 2009 66 5 563 570 19433655 61 Korczyn AD Keens J Oldham M Macrae S The safety and efficacy of ropinirole as early therapy in elderly patients with Parkinson’s disease Neurology 2008 54 7 Suppl 3 A90 62 Schapira AHV Neuroprotection and dopamine agonists Neurology 2002 58 4 Suppl 1 9 18 11781397 63 Whone AL Watts RL Stoessl AJ Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 2003 54 1 93 101 12838524 64 Ravina B Marek K Eberly S Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease Mov Disord 2012 27 11 1392 1397 22976926 65 Voon V Hassan K Zurowski M Prospective prevalence of pathologic gambling and medication association in Parkinson disease Neurology 2006 66 1 1750 1752 16769956 66 Weintraub D Siderowf AD Potenza MN Association of dopamine agonist use with impulse control disorders in Parkinson disease Arch Neurol 2006 63 7 969 973 16831966 67 Voon V Hassan K Zurowski M Prevalence of repetitive and reward-seeking behaviors in Parkinson disease Neurology 2006 67 7 1254 1257 16957130 68 Ferreira JJ Katzenschlager R Bloem BR Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease Eur J Neurol 2013 20 1 5 15 23279439 69 Fox SH Katzenschlager R Lim SY The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson’s disease Mov Disord 2011 26 Suppl 3 2 41 21322013 70 Ives NJ Stowe RL Marro J Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients BMJ 2004 329 7466 593 15310558 71 Stern M Parkinson Study Group A controlled trial of rasagiline in Parkinson’s disease patients with levodopa-related motor fluctuations (PRESTO Study) [abstract] Ann Neurol 2003 54 27 72 Management of Parkinson’s disease: an evidence-based review Mov Disord 2002 17 160 166 73 Thomas A Iacono D Luciano AL Armellino K Di Iorio A Onofrj M Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease J Neurol Neurosurg Psychiatry 2004 75 1 141 143 14707325 74 Elia AE Dollenz C Soliveria P Albanese A Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation Eur J Neurol 2012 19 1 76 83 21645174 75 Pfeiffer RF Potential of transdermal drug delivery in Parkinson’s disease Drugs Aging 2002 19 561 570 12207550 76 Ahlskog JE Beating a dead horse – dopamine and Parkinson disease Neurology 2007 69 17 1701 1711 17954785 77 Honig H Antonini A Martinez-Martin P Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life Mov Disord 2009 24 10 1468 1474 19425079 78 Deuschl G Schade-Brittinger C Krack P A randomized trial of deep-brain stimulation for Parkinson’s disease N Engl J Med 2006 355 9 896 908 16943402 79 Yu H Neimat JS The treatment of movement disorders by deep brain stimulation Neurotherapeutics 2008 5 1 26 36 18164481 80 Benabid AL Pollak P Gao D Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders J Neurosurg 1996 84 2 203 214 8592222 81 Kleiner-Fisman G Herzog J Fisman DN Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes Mov Disord 2006 21 Suppl 14 290 304 82 Hamani C Richter E Schwalb JM Lozan AM Bilateral subthalamic nucleus stimulation for Parkinson’s disease: a systematic review of the clinical literature Neurosurgery 2005 56 6 1313 1321 15918948 83 Schüpbach WM Maltête D Houeto JL Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial Neurology 2007 6 4 267 271 84 Derost PP Ouchchane L Morand D Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 2007 68 17 1345 1355 17452578 85 Odekerken VJ van Laar T Staal MJ Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial Lancet Neurol 2013 12 1 37 44 23168021 86 Okun MS Foote KD Subthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return? Arch Neurol 2005 62 4 533 536 15824249 87 Anderson VC Burchiel KJ Hogarth P Favre J Hammerstad JP Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease Arch Neurol 2005 62 4 554 560 15824252 88 Schneeberger A Mandler M Mattner F Schmidt W Vaccination for Parkinson’s disease Parkinsonism Relat Disord 2012 18 Suppl 1 11 13 89 Masliah E Rockenstein E Adame A Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease Neuron 2005 16 46 (6):857–868. 90 Gross C Rougier A Guehl D Boraud T Julien J Bioulac B High-frequency stimulation of the globus pallidus internalis in Parkinson’s disease: a study of seven cases J Neurosurg 1997 87 4 491 498 9322838 91 Pahwa R Wilkinson S Smith D Lyons K Miyawaki E Koller WC High-frequency stimulation of the globus pallidus for the treatment of Parkinson’s disease Neurology 1997 49 1 249 253 9222199 92 Kumar R Lang AE Rodriguez-Oroz MC Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson’s disease Neurology 2000 55 12 Suppl 6 34 39 93 Volkmann J Allert N Voges J Sturm V Schnitzler A Freund HJ Long-term results of bilateral pallidal stimulation in Parkinson’s disease Ann Neurol 2004 55 6 871 875 15174022 94 Visser-Vandewalle V van der Linden C Temel Y Nieman F Celik H Beuls E Long-term motor effect of unilateral pallidal stimulation in 26 patients with advanced Parkinson disease J Neurosurg 2003 99 4 701 707 14567606 95 Calne SM Kumar A Young onset Parkinson’s disease. Practical management of medical issues Parkinsonism Relat Disord 2008 14 2 133 142 17804273 96 Hoehn MM Yahr MD Parkinsonism: onset, progression, and mortality Neurology 1967 17 5 427 442 6067254 97 Jankovic J McDermott M Carter J Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group Neurology 1990 40 10 1529 1534 2215943 98 Merola A Zibetti M Artusi CA Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson’s disease: a role for age at disease onset? J Neurol Neurosurg Psychiatry 2012 83 3 251 257 22180646 99 Bronstein JM DeSalles A DeLong MR Stereotactic pallidotomy in the treatment of Parkinson’s Disease: an expert opinion Arch Neurol 1999 56 9 1064 1069 10488806 100 Marsac L Chauvet D Larrat B MR-guided adaptive focusing of therapeutic ultrasound beams in the human head Med Phys 2012 39 2 1141 1149 22320825 101 Hely MA Fung VSC Morris JGL Treatment of Parkinson’s Disease J Clin Neurosci 2000 7 6 484 494 11029227 102 InSightec ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Available from: http://clinicaltrials.gov/ct2/show/NCT01304758 NLM identifier: NCT01304758 Accessed July 10, 2013 103 Huang Y Hynynen K MR-guided focused ultrasound for brain ablation and blood–brain barrier disruption Methods Mol Biol 2011 711 579 593 21279624 104 Jeanmonod D Werner B Morel A Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain Neurosurg Focus 2012 32 1 1 105 Evans JR Barker RA Neurotrophic factors as a therapeutic target for Parkinson’s disease Expert Opin Ther Targets 2008 12 4 437 447 18348680 106 Poewe W Mahlknecht P Jankovic J Emerging therapies for Parkinson’s disease Curr Opin Neurol 2012 25 4 448 459 22772874 107 Astradsson A Cooper O Vinuela A Isacson O Recent advances in cell-based therapy for Parkinson disease Neurosurg Focus 2008 24 3–4 6 108 Santos CM New agents promote neuroprotection in Parkinson’s disease models CNS Neurol Disord Drug Targets 2012 11 4 410 418 22483311 109 Kirik D Rosenblad C Bjorklund A Mandel RI Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system J Neurosci 2000 20 12 4686 4700 10844038 110 Gasmi M Herzog CD Brandon EP Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease Mol Ther 2007 15 1 62 68 17164776 111 Freed CR Breeze RE Rosenberg NL Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease N Engl J Med 1992 327 22 1549 1555 1435881 112 Piccini P Brooks DJ Björklund A Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient Nat Neurosci 1999 2 12 1137 1140 10570493 113 Mendez I Sanchez-Pernaute R Cooper O Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson’s disease Brain 2005 128 7 1498 1510 15872020 114 Masliah E Rockenstein E Mante M Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease PLoS One 2011 6 4 193 198 115 LeWitt PA Rezai AR Leehey MA AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial Lancet Neurol 2011 10 4 309 139 21419704 116 Marks WJ Jr Bartus RT Siffert J Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial Lancet Neurol 2010 9 12 1164 1172 20970382 117 Linazasoro G Cell therapy for Parkinson’s disease: only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson’s disease Cell Transplant 2006 15 463 473 17121157 118 Farley BG Koshland GF Training BIG to move faster: the application of the speed–amplitude relation as a rehabilitation strategy for people with Parkinson’s disease Exp Brain Res 2005 167 3 462 467 16283401 119 Schenkman M Donovan J Tsubota J Kluss M Stebbins P Butler RB Management of individuals with Parkinson’s disease: rationale and case studies Phys Ther 1989 69 11 944 955 2813522 120 Sutoo D Akiyama K Regulation of brain function by exercise Neurobiol Dis 2003 13 1 1 14 12758062 121 Goodwin VA Richards SH Taylor RS Taylor AH Campbell JL The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis Mov Disord 2008 23 5 631 640 18181210 122 Lewis GN Byblow WD Walt SE Stride length regulation in Parkinson’s disease: the use of extrinsic visual cues Brain 2000 123 10 2077 2090 11004125